Australian Clinical Labs Faces Class Action Over 2022 Medlab Cyberattack

Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.

Australian Clinical Labs has disclosed that it is facing a representative class action in the Supreme Court of Victoria, brought on behalf of customers of Medlab Pathology and/or ACL whose personal information was compromised in a February 2022 cyberattack. The claim seeks damages for allegedly affected individuals based on alleged breaches of Australian Consumer Law and duties of care, although no quantum has been specified, and ACL denies the allegations and plans to vigorously defend the proceedings, highlighting ongoing legal and reputational risks stemming from the data breach.

The case underscores continuing fallout from past cyber incidents in the healthcare diagnostics sector, where data security and privacy obligations are increasingly under regulatory and public scrutiny. A protracted legal battle could entail financial exposure, legal costs and heightened compliance focus for ACL, while also serving as a signal to industry peers about the potential consequences of cyber vulnerabilities and alleged mishandling of patient data.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

More about Australian Clinical Labs Ltd

Australian Clinical Labs Limited is an Australian pathology and diagnostic testing provider, operating through brands including Medlab Pathology. The company serves healthcare providers and patients across Australia, focusing on laboratory testing services and handling sensitive personal and medical information for its customers.

Average Trading Volume: 838,781

Technical Sentiment Signal: Sell

Current Market Cap: A$380.1M

For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.